These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16328179)

  • 1. [Chronic kidney disease].
    Anders HJ
    Med Klin (Munich); 2005 Nov; 100(11):714-21. PubMed ID: 16328179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.
    Yokoyama K
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214
    [No Abstract]   [Full Text] [Related]  

  • 3. Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients.
    Owda AK; Alam MG; Kumar J
    N Engl J Med; 2004 Jul; 351(2):188-9; author reply 188-9. PubMed ID: 15247361
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
    Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
    Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
    Tahara H
    Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet: benefit and cost.
    Cohen E
    Nephrol Dial Transplant; 2008 Apr; 23(4):1460; author reply 1460. PubMed ID: 18065795
    [No Abstract]   [Full Text] [Related]  

  • 7. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study.
    Evenepoel P; Sprangers B; Lerut E; Bammens B; Claes K; Kuypers D; Meijers B; Vanrenterghem Y
    Clin Transplant; 2012; 26(3):393-402. PubMed ID: 22007637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means.
    Drüeke TB
    Pediatr Nephrol; 2005 Mar; 20(3):399-403. PubMed ID: 15662538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet cost and utility in dialysis patients.
    Cohen E; Uribarri J
    Semin Dial; 2005; 18(4):353-4. PubMed ID: 16076364
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cinacalcet - an allosteric enhancer at the Ca2+-receptor].
    Kebig A; Mohr K
    Dtsch Med Wochenschr; 2008 Aug; 133(33):1681-3. PubMed ID: 18661462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation].
    Vaquero E; Esteban de la Rosa RJ; Oliva N; Fernández Castillo R; Fernández Gallegos R; Bravo Soto J
    Med Clin (Barc); 2012 Apr; 138(8):323-6. PubMed ID: 21492884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fooling the parathyroid gland--will there be health benefits?
    Curhan G
    N Engl J Med; 2004 Apr; 350(15):1565-7. PubMed ID: 15071132
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism.
    Bahner U; Brandl M; Nies C; Schmidt-Gayk H
    J Ren Nutr; 2008 Jul; 18(4):383-8. PubMed ID: 18558304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective.
    Garside R; Pitt M; Anderson R; Mealing S; D'Souza R; Stein K
    Nephrol Dial Transplant; 2007 May; 22(5):1428-36. PubMed ID: 17308322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
    Mercadal Orfila G; Blasco Mascaró I
    Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.